Among patients with advanced PIK3CA-mutated, HR-positive/HER2-negative breast cancer, Itovebi-based treatment generated positive overall survival results.

Biomedical engineers at Duke University have developed an AI-based platform that designs short proteins, termed peptides, ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

This study presents fundamental insights into overcoming resistance in hormone receptor-positive breast cancer by demonstrating that sustained CDK4/6 inhibitor treatment, either alone or in ...

Below is a detailed analysis of the two drugs secured by Cosmos Health. Abstract #1: ESTERS OF STEROIDAL LACTAM AND BIS (2-CHLOROETHYL) AMINOPHENOXY PROPANOIC ACID DERIVATIVES; Patent International ...

However, testing for a complex karyotype is important because it provides ... and about 20% had previously received a PI3K inhibitor. The response rates are similar across several key clinical factors ...

Recent studies show that inhibiting the Arp2/3 complex subunit ARPC2 can suppress cancer cell migration while sparing normal cells. Notably, two ARPC2-binding inhibitors have been FDA-approved for ...

A separate retrospective analysis of a larger cohort of 1091 patients with advanced NSCLC who were progression-free after at least 2 years of immune checkpoint inhibitor therapy similarly did not find ...

The biogenesis of EVs is a complex process that involves multiple cellular pathways ... of protective networks within the cardiovascular system, including the AMPK/PI3K/AKT pathway, transforming ...

Future Virology. 2012;7(11):1089-1101. Patients with advanced fibrosis or cirrhosis treated with PI triple therapy also showed diminished SVR rates, possibly related to reduced IFN responsiveness ...

Combined MEK and PI3K inhibition has had limited success in the clinic, although alternative methods of targeting these pathways may be effective. MEK inhibitors form the backbone of multiple ...